- Home
- PODD
PODD
Insulet Corporation
as 12-18-2024 11:41am EST
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.
| Founded: | 2000 | Country: | United States |
| Employees: | N/A | City: | ACTON |
| Market Cap: | 16.5B | IPO Year: | 2007 |
| Target Price: | $265.81 | AVG Volume (30 days): | 528.9K |
| Analyst Decision: | Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 5.74 | EPS Growth: | 235.68 |
| 52 Week Low/High: | $160.19 - $279.77 | Next Earning Date: | 11-07-2024 |
| Revenue: | $1,983,900,000 | Revenue Growth: | 27.42% |
| Revenue Growth (this year): | 23.56% | Revenue Growth (next year): | 18.07% |
Stock Insider Trading Activity of Insulet Corporation (PODD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Benjamin Eric | PODD | EVP, CPXPO | Dec 16 '24 | Sell | $267.60 | 4,362 | $1,167,271.20 | 18,702 | |
| Budden Lauren | PODD | Group VP, CAO and Controller | Dec 10 '24 | Sell | $275.62 | 915 | $252,192.30 | 5,733 | |
| BORIO LUCIANA | PODD | Director | Nov 12 '24 | Sell | $274.80 | 508 | $139,598.40 | 2,790 |
Latest Insulet Corporation News
PODD Breaking Stock News: Dive into PODD Ticker-Specific Updates for Smart Investing
Zacks
5 days ago
Why Insulet (PODD) is a Top Momentum Stock for the Long-Term
Zacks
6 days ago
RMD or PODD: Which Is the Better Value Stock Right Now?
MT Newswires
6 days ago
Nephron Research Adjusts Price Target on Insulet to $310 From $285
MT Newswires
6 days ago
JPMorgan Raises Insulet Price Target to $330 From $280, Maintains Overweight Rating
Investor's Business Daily
7 days ago
Inari Medical Stock Gets RS Rating Upgrade
MT Newswires
7 days ago
Wells Fargo Adjusts Price Target on Insulet to $305 From $290, Keeps Overweight Rating
MT Newswires
7 days ago
Citigroup Raises Price Target on Insulet to $310 From $283, Keeps Buy Rating
Argus Research
8 days ago
PODD: Raising target price to $289.00
Compare PODD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PODD Insulet Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.